Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
BMJ Open ; 13(6): e071973, 2023 06 13.
Article in English | MEDLINE | ID: covidwho-20235334

ABSTRACT

OBJECTIVE: To quantify differences in number and timing of first primary cleft lip and palate (CLP) repair procedures during the first year of the COVID-19 pandemic (1 April 2020 to 31 March 2021; 2020/2021) compared with the preceding year (1 April 2019 to 31 March 2020; 2019/2021). DESIGN: National observational study of administrative hospital data. SETTING: National Health Service hospitals in England. STUDY POPULATION: Children <5 years undergoing primary repair for an orofacial cleft Population Consensus and Surveys Classification of Interventions and Procedures-fourth revisions (OPCS-4) codes F031, F291). MAIN EXPOSURE: Procedure date (2020/2021 vs 2019/2020). MAIN OUTCOMES: Numbers and timing (age in months) of first primary CLP procedures. RESULTS: 1716 CLP primary repair procedures were included in the analysis. In 2020/2021, 774 CLP procedures were carried out compared with 942 in 2019/2020, a reduction of 17.8% (95% CI 9.5% to 25.4%). The reduction varied over time in 2020/2021, with no surgeries at all during the first 2 months (April and May 2020). Compared with 2019/2020, first primary lip repair procedures performed in 2020/2021 were delayed by 1.6 months on average (95% CI 0.9 to 2.2 months). Delays in primary palate repairs were smaller on average but varied across the nine geographical regions. CONCLUSION: There were significant reductions in the number and delays in timing of first primary CLP repair procedures in England during the first year of the pandemic, which may affect long-term outcomes.


Subject(s)
COVID-19 , Cleft Lip , Cleft Palate , Child , Humans , COVID-19/epidemiology , Electronic Health Records , Cleft Lip/epidemiology , Cleft Lip/surgery , Cleft Palate/epidemiology , Cleft Palate/surgery , Pandemics , State Medicine , England/epidemiology
2.
Nucleic Acids Res ; 49(W1): W619-W623, 2021 07 02.
Article in English | MEDLINE | ID: covidwho-1246737

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic will be remembered as one of the defining events of the 21st century. The rapid global outbreak has had significant impacts on human society and is already responsible for millions of deaths. Understanding and tackling the impact of the virus has required a worldwide mobilisation and coordination of scientific research. The COVID-19 Data Portal (https://www.covid19dataportal.org/) was first released as part of the European COVID-19 Data Platform, on April 20th 2020 to facilitate rapid and open data sharing and analysis, to accelerate global SARS-CoV-2 and COVID-19 research. The COVID-19 Data Portal has fortnightly feature releases to continue to add new data types, search options, visualisations and improvements based on user feedback and research. The open datasets and intuitive suite of search, identification and download services, represent a truly FAIR (Findable, Accessible, Interoperable and Reusable) resource that enables researchers to easily identify and quickly obtain the key datasets needed for their COVID-19 research.


Subject(s)
Biomedical Research , COVID-19 , Databases, Factual , Datasets as Topic , Information Dissemination , Open Access Publishing , SARS-CoV-2 , COVID-19/epidemiology , COVID-19/genetics , COVID-19/virology , Databases, Bibliographic , Disease Outbreaks , Humans , Pandemics , SARS-CoV-2/chemistry , SARS-CoV-2/genetics , SARS-CoV-2/metabolism , SARS-CoV-2/ultrastructure , Time Factors , Viral Proteins/chemistry , Viral Proteins/genetics
4.
Strategy & Leadership ; 48(5):41-47, 2020.
Article in English | ProQuest Central | ID: covidwho-915990

ABSTRACT

1 The pandemic’s impact has been profound and has extended beyond its economic consequences for individual businesses and industries, posing a calamitous threat to those infected and to the global supply chain and social stability worldwide. The politics of pandemic speech Before the actual dangers of the virus were fully apparent, U.S. President Donald Trump used daily press briefings to make unremittingly positive claims downplaying the risk of an epidemic and asserting the virus did not pose a significant risk to the nation. Critics have suggested his “happy talk” was actually intended to reassure the stock market, maintaining its earlier gains being a critical element of his re-election strategy. On March 3, 2020 – three weeks before his COVID-19 diagnosis and hospitalization– UK Prime Minister Boris Johnson said: “I was at a hospital the other night where I think there were actually a few coronavirus patients and I shook hands with everybody, you’ll be pleased to know, and I continue to shake hands.”

SELECTION OF CITATIONS
SEARCH DETAIL